The rise of copyright’s blockbuster initially drove a surge for pharma, but recent developments present a uncertain outlook for shareholders. Off-patent alternatives are eroding profits, and persistent legal battles https://ianylrs865399.atualblog.com/47858166/sildenafil-and-pharma-a-precarious-play